Acquired hemophilia A: a narrative review and management approach in the emicizumab era
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2024.09.040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Patrick Ellsworth und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; University of North Carolina…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Hemophilia A, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Novo Nordisk USA, Pfizer.
Abstract (Originalsprache)
Acquired hemophilia A (AHA) is a rare bleeding disorder caused by inhibitory autoantibodies to factor (F)VIII. The goals of treatment are 2-fold, namely immunosuppressive therapy to eradicate the inhibitor and hemostatic management to control bleeding. Emicizumab, a bispecific antibody that acts as a FVIIIa-mimetic, has seen growing use in AHA following its approval for congenital hemophilia A. This review provides an overview of the epidemiology, pathophysiology, diagnosis, and treatment of AHA. Registry, trial, and case series data are assimilated and summarized with an emphasis on a standardized approach that integrates the use of emicizumab. With recent registry data suggesting the need to focus on immunosuppression-related mortality in AHA, we provide treatment recommendations in an algorithmic format that have become the standard of care at our institution. These recommendations are intended to minimize hemostatic product usage and potential toxicity related to immunosuppressive therapy while reducing morbidity and rehospitalization rates for bleeding. The proposed treatment algorithm, which includes key interventions by phase of therapy, can be readily implemented at centers that have rapid access to plasma FVIII activity using a one-stage assay. A case is presented to illustrate the proposed diagnostic and management considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; University of North Carolina Blood Research Center, Chapel Hill, NC 27599, USA. Electronic address…
- Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC 27599, USA.
- Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; University of North Carolina Blood Research Center, Chapel Hill, NC 27599, USA.
Förderung
- Novo Nordisk USA
- Pfizer
Zitieren
APA
Ellsworth, P., Chen, S. L., Jones, L. A., Ma, A. D., & Key, N. S. (2025). Acquired hemophilia A: a narrative review and management approach in the emicizumab era. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.09.040
Vancouver
Ellsworth P, Chen SL, Jones LA, Ma AD, Key NS. Acquired hemophilia A: a narrative review and management approach in the emicizumab era. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.09.040
BibTeX
@article{Ellsworth2025,
author = {Ellsworth, Patrick and Chen, Sheh-Li and Jones, Lee Ann and Ma, Alice D and Key, Nigel S},
title = {Acquired hemophilia A: a narrative review and management approach in the emicizumab era},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2024.09.040}
}
EUVIMED